In Europe, the technology R&D Framework Programmes (FP) have since 1984 been the main financial instrument used by the European Commission, the EU executive body, to guide and sustain research for technological innovation based on trans-national collaboration. In these 25 years, there have been seven FPs: FP7, the latest, was put into effect in 2007 and will be completed in 2013.
The earliest nanotechnology research projects were financed starting with FP3 (1991-1994), but it was only when FP6 came of age (2002) (2003) (2004) (2005) (2006) ) that one of the priority research areas was specifically dedicated to the topic -Nanosciences, nanotechnologies, materials & new production technologies, NMP. This growing attention to nanotechnologies was accompanied not only by increasing resources spent on them but also wider research.
Three research projects on the EHS impact of these technologies have been financed under FP5, fifteen under FP6 and ten already in the first two years of FP7; the sums involved have risen from 2.5 million for FP5 (about 0.6 M/yr over four years), to about 28 M in FP6 (about 1.2 M/yr over five years), and have reached 10 M in the first two years of FP7, i.e. 5 M/yr. The European Commission's latest estimates say that the total nanotechnology budget, including FP7 financing, and the corresponding investments in Member States, could reach about 100 M by 2013 11, 12) .
Research has gradually shifted from a sharp focus on technological development to broader questions of responsible, sustainable development to take account of the EHS impact of these technologies. These projects have clear implications for occupational safety and health (OSH).
There also appears to be progress in the approach to research projects. FP5 basically involved "scattered" studies of the issues that started to come to light on the emerging risk. However, in FP6 the focus had already moved ahead to toxicological aspects and capacity building. Now, under FP7, projects are mainly concerned with developing a critical mass and finding the answers to key questions related to risk analysis. These center on toxicity and health effects, methods for environmental measurements and monitoring, developing models for use in real exposure conditions, criteria for health surveillance, and risk communication.
Editorial Challenges and Perspectives of Occupational Health and Safety Research in Nanotechnologies in Europe
Although the whole scientific community has now put its back into narrowing the gaps in scientific knowledge, and promoting research with a view to tackling the potential risks of nanotechnologies, we are still far from any firm agreement. At the same time there has been extensive debate 13) , involving regulators, policy-makers, industry, researchers and society as a whole, and many proposals have been aired in order to develop a governance for sustainable and safe nanotechnologies. In the uncertainties due to limited knowledge there are different proposed approaches: we can take a "laissez-faire" attitude; establish a moratorium on R&D and/or marketing of nanotechnologies; put our faith in voluntary measures; set up a process of thorough regulation specifically regarding nanotechnologies; put in motion an incremental process making the fullest possible use of existing legislation, introducing modifications and, where necessary, amendments.
There is thus a wide range of options, but there does seem to be a tendency towards the idea of using existing regulations, adapting them to nanotechnology, as the need arises, reinforcing them by applying the precautional principle. This approach, formulated in general terms, would include boosting research and analysis for proper risk assessment; promoting production that is sustainable for mankind and the environment; cost-benefit analysis of measures for prevention, and integrated, multidisciplinary strategies from all stakeholders, designed to improve health, the environment, competitivity and work.
In order to respond to these needs OSH research will have to focus on the key questions that are still open, especially those on risk management to safeguard the health of the increasing numbers of workers who will be employed in these various sectors.
Close transnational cooperation throughout Europe will be needed, and also with the USA and Japan, to achieve the necessary critical mass. Efforts must be coordinated and integrated, with easy access to information, and to industrial nanotechnology R&D. Research on safety for consumers of drugs, foodstuffs and the environment should not be viewed as a separate sector, but must be more closely integrated 14, 15) .
One last point: development must bear in mind the need for effective communication and for a global governance platform for nanotechnology. Society needs a proper response to this challenge from an innovative sector, which, if correctly managed and developed responsibly and sustainably, offers great prospects for benefits for mankind.
